Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy

Abstract

Sir, Response to Dr Sanjay et al We wish to thank Sanjay et al for spotting the typo in our report on the awareness and use of nutritional supplementations for patients with age-related macular degeneration. We stand corrected: only 9.2-30% were familiar with this condition as a cause for loss of vision. We would like to take this opportunity to congratulate our colleagues in Singapore for their excellent work in furthering the dissemination of information on this critically important topic and hope that their efforts will be imitated worldwide.

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients

“…But aqueous VEGF is not significantly elevated in eyes with CSC. 16,[23][24][25] Moreover, there appears to be significant individual variation in treatment responses to IVB. 9,20 CSC encompasses a wide range of patients with varying degrees and patterns of angiographical and tomographical manifestations.…”

“…[9][10][11][12][13][14] Intravitreal bevacizumab (IVB), a recombinant humanized monoclonal anti-VEGF antibody, has been reported to be effective in CSC patients with symptom durations over 3 months. 9,[15][16][17][18][19][20] In acute CSC of o3 months symptom duration, IVB may not result in therapeutic benefits compared with simply waiting for spontaneous resolution. 21,22 It is not clear why and how IVB induces the absorption of subretinal fluid (SRF) in CSC.…”

Micropulse diode laser versus bevacizumab in chronic central serous chorioretinopathy: a pilot study

“…Artunay and colleagues in a prospective open labeled non randomized trial comprising of 30 eyes with chronic symptomatic CSC reported significant improvement with single injection Bevacizumab. 15 In a retrospective analysis Kim et al noted that good responders to Avastin had smaller lesions and thicker choroids. 16 However Liu et al in a meta-analysis and review concluded that there was insufficient evidence for the superiority of Bevacizumab over other modalities.…”

Central serous retinopathy

“…Intravitreal anti-vascular endothelium growth factor (anti-VEGF) therapy with bevacizumab has been reported with favorable results in case series, particularly in patients with chronic disease (53)(54)(55)(56)(57)(58)(59). Reduction of choroidal hyperpermeability has been proposed as a mechanism, as VEGF plays a role in the maintenance of choroidal vascular permeability, and recent data demonstrate that the choroid is abnormally thickened in these patients (60,61).…”